SuperworthCorcept Therapeutics CORT
- Market cap
- $9.3B
- PE
- 204×
- 10y median 28.3×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 11.2×
- EV/EBIT
- n/m
- a sliver of operating profit
- Revenue, 12 months
- $830.8M
- +16% on a year ago
- Net margin
- 6.6%
- Free cash flow yield
- 1.2%
Corcept Therapeutics trades at 204× trailing earnings, pricier than 94% of the last ten years. Revenue was $830.8M over the last twelve months, up 16% on a year earlier with a 7% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $123.6M+22% | $135.4M+31% | $146.8M+39% | $163.8M+39% | $182.5M+48% | $181.9M+34% | $157.2M+7% | $194.4M+19% | $207.6M+14% | $202.1M+11% | $164.9M+5% | $256.1M+32% | |
| Cost of revenue | $1.6M+23% | $1.9M+27% | $2.5M+83% | $2.5M+60% | $2.9M+74% | $3M+58% | $2.4M−5% | $3.4M+36% | $4.6M+60% | $2.5M−14% | $2.9M+20% | $4.1M+18% |
| Gross profit | $122M+22% | $133.5M+32% | $144.3M+38% | $161.3M+39% | $179.7M+47% | $178.9M+34% | $154.8M+7% | $191M+18% | $203M+13% | $199.6M+12% | $162M+5% | $252.1M+32% |
| R&D | $45.5M+37% | $54.7M+49% | $58.5M+43% | $58.7M+36% | $59.3M+30% | $70.3M+29% | $60.7M+4% | $60.5M+3% | $68.8M+16% | $64.9M−8% | $66.3M+9% | $53.9M−11% |
| SG&A | $45.3M+29% | $47.2M+11% | $56.3M+16% | $66.9M+55% | $73.7M+63% | $83.4M+77% | $90.7M+61% | $103.9M+55% | $124M+68% | $130.2M+56% | $145.4M+60% | $156.9M+51% |
| $31.2M−2% | $31.7M+41% | $29.5M+99% | $35.6M+20% | $46.6M+50% | $25.3M−20% | $3.4M−88% | $26.7M−25% | $10.2M−78% | $4.5M−82% | −$49.6M | $41.3M+55% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | $36.4M+10% | $36.8M+52% | $35M+90% | $41.6M+26% | $52.9M+46% | $32M−13% | $9.6M−73% | $31.7M−24% | $15.2M−71% | $9.9M−69% | −$44.7M | $45.9M+45% |
| $5M | $5.5M−29% | $7.2M+183% | $6.1M+13% | $5.7M+14% | $1.2M−78% | −$10.9M | −$3.5M | −$4.4M | −$14.4M | −$13M+19% | $2.9M | |
| Net income | $31.4M−9% | $31.4M+89% | $27.8M+75% | $35.5M+29% | $47.2M+51% | $30.7M−2% | $20.5M−26% | $35.1M−1% | $19.7M−58% | $24.3M−21% | −$31.8M | $43M+22% |
| $0.28−7% | $0.28+100% | $0.25+79% | $0.32+28% | $0.41+46% | $0.26−7% | $0.17−32% | $0.29−9% | $0.16−61% | $0.20−23% | −$0.30 | $0.36+24% | |
| 111.1M−5% | 110.8M−5% | 109.9M−5% | 111.2M+2% | 113.7M+2% | 119.2M+8% | 119.8M+9% | 120.5M+8% | 119.4M+5% | 120M+1% | 104.4M−13% | 118.4M−2% |
Gross profit: 57 periods, Q2 FY12 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 7 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY10 and Q4 FY11: not printed by the filing, worked out from its own lines. 3 periods, Q4 FY12 to Q4 FY14: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 11 periods, Q4 FY15 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Corcept Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CORTCorcept Therapeutics | $9.3B | 204× | 28.3× | 11.2× | +16% | 6.6% | |
| PTGXProtagonist Therapeutics | $9B | 134× | 58.3× | 31.8× | +35% | 29.4% | |
| TGTXTG Therapeutics | $8.3B | 19.8× | 19.4× | 10.4× | +76% | 55.2% | |
| BMRNBiomarin Pharmaceutical | $10.8B | 151× | 70.6× | 3.2× | +11% | 2.1% | |
| ALKSAlkermes plc. | $7.3B | 115× | 16.0× | 4.4× | +11% | 4.0% | |
| AMRXAmneal Pharmaceuticals | $6.5B | 41.6× | 51.5× | 2.1× | +9% | 5.0% | |
| JAZZJazz Pharmaceuticals | $13.9B | 14.6× | 20.2× | 3.0× | +13% | 20.4% | |
| LGNDLigand Pharmaceuticals | $6.1B | 32.3× | 37.7× | 20.8× | +55% | 67.9% | |
| KNSAKiniksa Pharmaceuticals International | $6B | 79.1× | 85.3× | 7.1× | +59% | 9.6% | |
| INDVIndivior Pharmaceuticals | $4.1B | 12.4× | 20.1× | 3.1× | +13% | 26.7% | |
| ARQTArcutis Biotherapeutics | $3.9B | 142× | 115× | 8.5× | +76% | 6.1% | |
| Peer median | $6.9B | 60.3× | 44.6× | 5.8× | +24% | 15.0% |
More on Corcept Therapeutics
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .